WillItSurvive
Pharma and healthcare groups · United States

Cardinal Health

cardinalhealth.com ↗

Drug and medical supply wholesaler delivering to most US hospitals and pharmacies.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from August 11, 2026 · Every call on the record Checkpoint: Q4/FY2026 earnings report
The call

Cardinal Health sits inside a three-company system moving most of the US drug supply, with AI so far used to trim its own costs, not to unseat it.

Cardinal Health moves prescription drugs from manufacturers to hospitals and pharmacies across America, handling over a trillion dollars in medicines yearly. It is extremely hard to compete with because the US government requires special licenses to distribute drugs, Cardinal owns massive physical warehouses and delivery networks across the country, and hospitals have long-standing contracts with them that would be expensive to switch. No company has successfully built a real alternative. However, the picture could shift if drug makers change how they pay Cardinal to deliver new weight-loss drugs, or if cheaper copies of those drugs flood the market and shrink profits.

Why
01
AI pressure: None apparent. AI tools like Skan AI cut Cardinal's own write-offs from $20M to $30K, boosting margins rather than threatening its distribution role. Could AI do the core job? Unlikely.
02
Bigger players: Amazon Business/Amazon Pharmacy. Amazon has piloted direct hospital and pharmacy shipping but hasn't matched Cardinal's DEA-licensed, 100,000-point delivery network. Could a giant copy it? No, they are blocked.
03
What protects it. DEA distribution licenses, decades-old hospital and manufacturer contracts, and physical reach to 75%+ of US hospitals.
What would change this call
Cardinal Health reports FY2026 Q4 earnings on August 11, 2026. Shows whether GLP-1 driven revenue growth and margin trends continue.
Further goodwill impairments tied to Solaris Health, GI Alliance, or ION acquisitions. Would show MSO acquisition strategy overpaying for assets.
Manufacturers renegotiate GLP-1 distribution margins or biosimilar entry accelerates. Would show the current growth driver compressing.
Key numbers
  • Q3 FY26 revenue $60.9B, up 11% YoY (2026-04-30)
  • Top 3 distributors hold >90% of US market (2026-07-20)
  • $184M goodwill impairment booked Q3 FY26 (2026-04-30)
Named risks
  • Ongoing and new opioid-related litigation and settlements beyond current reserves. Severity: high
  • MSO acquisition integration failures, evidenced by $184M Q3 FY2026 goodwill impairment. Severity: medium
  • GLP-1 revenue concentration on thin wholesale margins vulnerable to manufacturer renegotiation. Severity: medium
  • Tariff exposure already pressuring GMPD segment profit, down to $25M in Q3 FY2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
McKesson CorporationcontestingHolds ~24.5% of US drug distribution vs Cardinal's ~16.5% as of Feb 2026
Cencora (formerly AmerisourceBergen)contestingHolds ~18% market share, part of Big Three oligopoly controlling >90% as of Feb 2026
MedlinecontestingPrivate company holds ~11% of medical-surgical distribution, per Feb 2026 market data
Questions people ask
Is Cardinal Health profitable in 2026?
Yes. Cardinal Health posted Q3 FY2026 revenue of $60.9 billion (up 11% year over year) and non-GAAP diluted EPS of $3.17, up 35%, as of April 30, 2026, and raised its full-year EPS guidance to $10.70-$10.80.
Who is Cardinal Health's biggest competitor?
Cardinal Health competes with McKesson (about 24.5% of US drug distribution) and Cencora, formerly AmerisourceBergen (about 18%). Together with Cardinal's roughly 16.5% share, these three control over 90% of the roughly $1 trillion US drug distribution market as of February 2026.
Could AI replace Cardinal Health's business?
Unlikely soon. Cardinal's core moat is DEA licensing, physical distribution to over 100,000 locations, and contracts covering 75%+ of US hospitals, none of which AI-native entrants have replicated. Cardinal instead uses AI internally, cutting write-offs from $20 million to $30,000 in six months per a February 2026 case study.
Who owns Cardinal Health?
Cardinal Health is publicly traded on NYSE under ticker CAH with no controlling parent, and had a market capitalization of roughly $53.5-53.9 billion as of mid-July 2026. It spun off its CareFusion clinical technology unit in 2009.
How much opioid liability does Cardinal Health still owe?
Cardinal's share of the 2022 multistate opioid settlement is approximately $6.0-6.4 billion paid over an 18-year schedule starting 2022-02-25. A separate $700 million class-action settlement for acute-care hospitals was court-approved on 2025-03-05.
Why did Cardinal Health take a goodwill impairment in 2026?
Cardinal Health recorded a $184 million goodwill impairment charge in Q3 FY2026 (reported April 30, 2026), flagged as an early warning that some assets acquired through its MSO strategy, including GI Alliance and Solaris Health, are not fully living up to purchase price.
Timeline
  • 2026-07-14Stock near 52-week high of $243.21, up 46% over one year
  • 2026-06-30Trailing-twelve-month revenue reaches approximately $250.7 billion
  • 2026-04-30Q3 FY2026: $60.9B revenue (+11%), EPS $3.17 (+35%), $184M goodwill impairment
  • 2026-03-31Patricia Hemingway Hall becomes Board Chair after Gregory Kenny retires
  • 2026-02-09Skan AI case study shows write-offs cut from $20M to $30K in 6 months
  • 2025-11-03Completes $2.4 billion acquisition of urology MSO Solaris Health
  • 2025-08-12Reports Q4 and full-year FY2025 results, raises FY2026 guidance
  • 2025-03-26Profiles AI Center of Excellence, established 2021, led by Anagha Vyas
  • 2025-03-05$700 million opioid class-action settlement for acute-care hospitals approved
  • 2022-02-25Distributors approve $26B multistate opioid settlement; Cardinal share ~$6.0-6.4B
Head to head
Cardinal Health vs McKesson
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources